Advancing radiopharmaceuticals from bench to bedside requires integrated preclinical infrastructure, reliable access to radionuclides, and cross-sector collaboration.
This meeting convenes hospitals, preclinical and clinical researchers, emerging radiopharma companies, global pharma, and ecosystem partners to exchange international best practices, share national initiatives, and discuss strategic priorities for establishing Norway as a preferred destination for radiopharmaceutical preclinical and clinical research.
The event is supported by UiO:Life Science, and Director Carl Henrik Gørbitz will give the final talk «Radiopharmacy from discipline to societal impact».